131 related articles for article (PubMed ID: 14996767)
1. Olanzapine vs haloperidol for treatment of schizophrenia.
Amin M; Shukla VS
JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996767
[No Abstract] [Full Text] [Related]
2. Olanzapine vs haloperidol for treatment of schizophrenia.
Glazer WM
JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766
[No Abstract] [Full Text] [Related]
3. [Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].
Dilla T; Prieto L; Ciudad A; Sacristán JA
Actas Esp Psiquiatr; 2004; 32(5):269-79. PubMed ID: 15529211
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Lindner LM; Marasciulo AC; Farias MR; Grohs GE
Rev Saude Publica; 2009 Aug; 43 Suppl 1():62-9. PubMed ID: 19669066
[TBL] [Abstract][Full Text] [Related]
5. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.
Bounthavong M; Okamoto MP
J Eval Clin Pract; 2007 Jun; 13(3):453-60. PubMed ID: 17518814
[TBL] [Abstract][Full Text] [Related]
6. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
8. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population.
Gibson PJ; Damler R; Jackson EA; Wilder T; Ramsey JL
Value Health; 2004; 7(1):22-35. PubMed ID: 14720128
[TBL] [Abstract][Full Text] [Related]
9. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine vs haloperidol for treatment of schizophrenia.
Kunz M
JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996768
[No Abstract] [Full Text] [Related]
11. [Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].
Sacristán JA; Gómez JC; Salvador-Carulla L
Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1997; 25(4):225-34. PubMed ID: 9412161
[TBL] [Abstract][Full Text] [Related]
12. Assessing a drug's cost-benefits.
Raleigh F
Psychiatr Serv; 1996 Aug; 47(8):877-8. PubMed ID: 8837167
[No Abstract] [Full Text] [Related]
13. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
[TBL] [Abstract][Full Text] [Related]
14. Olanzapine vs haloperidol for treatment of schizophrenia.
Volavka J; Citrome L
JAMA; 2004 Mar; 291(9):1064; author reply 1065-6. PubMed ID: 14996765
[No Abstract] [Full Text] [Related]
15. The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
Am J Manag Care; 1999 Jul; 5(10 Suppl):S583-90. PubMed ID: 10539493
[TBL] [Abstract][Full Text] [Related]
16. Reduction in tardive dyskinesia symptoms during treatment with olanzapine or haloperidol.
Kinon BJ; Kollack-Walker S; Stauffer V; Liu-Seifert H
J Clin Psychopharmacol; 2012 Jun; 32(3):420-2. PubMed ID: 22561475
[No Abstract] [Full Text] [Related]
17. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
18. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Saddichha S; Ameen S; Akhtar S
J Clin Psychopharmacol; 2008 Feb; 28(1):27-31. PubMed ID: 18204337
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.
Glazer WM; Johnstone BM
J Clin Psychiatry; 1997; 58 Suppl 10():50-4. PubMed ID: 9265917
[TBL] [Abstract][Full Text] [Related]
20. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
Keefe RS; Seidman LJ; Christensen BK; Hamer RM; Sharma T; Sitskoorn MM; Lewine RR; Yurgelun-Todd DA; Gur RC; Tohen M; Tollefson GD; Sanger TM; Lieberman JA
Am J Psychiatry; 2004 Jun; 161(6):985-95. PubMed ID: 15169686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
